Frankfurt Rhine-Main Metropolitan Area
Strategic executive with an internationally recognized expertise in clinical development and outstanding record of delivering successful large-scale clinical trials on time leading to a number of successful new drug entries to market Respected, influential leader with inspirational leadership style, able to build and motivate multinational teams to deliver new medicines to patients Strategic skills to manage a diverse portfolio of multiple development candidates
Leading cardiovascular clinical development externally recognized as one of the fastest in drug development worldwide, built multinational team and engaged staff around shared goals – achieving several outstanding milestones: Conceptionalized and directed development of Xarelto© (Rivaroxaban) an oral direct FXa inhibitor, one of the largest and most complex development programs in the industry with 75,000 patients. In its first indication, Xarelto© was developed and approved in just 78 months.